Pericarditis during chemoimmunotherapy for non-small cell lung cancer: an adverse event to prevent and recognise

Eur J Cancer. 2021 May:149:114-116. doi: 10.1016/j.ejca.2021.03.004. Epub 2021 Apr 12.

Authors

Francesca Jacobs¹, Simona Carnio², Paola De Stefanis³, Alessia Luciano³, Silvia Novello²

Affiliations

¹ Department of Oncology, University of Torino, San Luigi Gonzaga University Hospital, Orbassano, Italy. Electronic address: francesca.jacobs@edu.unito.it.
² Department of Oncology, University of Torino, San Luigi Gonzaga University Hospital, Orbassano, Italy.
³ Cardiology Division, San Luigi Gonzaga University Hospital, Orbassano, Italy.

PMID: 33857885
DOI: 10.1016/j.ejca.2021.03.004

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / immunology
Carcinoma, Non-Small-Cell Lung / secondary
Cardiotoxicity
Glucocorticoids / administration & dosage
Humans
Immune Checkpoint Inhibitors / adverse effects*
Lung Neoplasms / drug therapy*
Lung Neoplasms / immunology
Lung Neoplasms / pathology
Male
Middle Aged
Pericarditis / chemically induced*
Pericarditis / diagnosis
Pericarditis / drug therapy
Risk Factors
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Glucocorticoids
Immune Checkpoint Inhibitors
pembrolizumab